Azathioprine: Clinical pharmacology and current indications in autoimmune disorders

BioDrugs

Volumn 9, Issue 1, 1998, Pages 33-47

  Anstey, Alex ^a   Lear, John T ^b  

^a ROYAL GWENT HOSPITAL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; CIMETIDINE; FUROSEMIDE; INDOMETACIN; NEUROMUSCULAR DEPOLARIZING AGENT; PENICILLAMINE;

AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; DRUG CARCINOGENICITY; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG USE; GASTROINTESTINAL SYMPTOM; HUMAN; LACTATION; MUTAGENICITY; PREGNANCY; PRIORITY JOURNAL; REVIEW;

EID: 0031973918     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809010-00004     Document Type: Review

References (140)

1. Drela N, Sitnicka E. Effect of azathioprine on the early stages of human lymphocyte orientation. Arch Immunol Ther Exp (Warsz) 1986; 34: 209-15
2. Gorski A, Korczak-Kowalska A, Nowaczyk G, et al. The effect of azathioprine on terminal differentiation of human B lymphocytes. Immunopharmacology 1983; 6: 259-66
3. Duclos H, Maillot MC, Galanaud P. Differential effects of azathioprine on T cells regulating murine B-cell function. Immunology 1982; 46: 595-601
4. Cook JD, Lai W, McGrane B. The effect of concentrations of mitogens on the immunosupressive action of azathioprine and prednisolone on human lymphocytes in vitro. J Immunopharmacol 1983; 5: 257-75
5. Al-Safi SA, Maddocks JL. Azathioprine and 6-mercaptopurine suppress the human mixed lymphocyte reaction by different mechanisms. Br J Clin Pharmacol 1984; 17: 417-22
6. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction to 6-mercaptopurine. Cancer Res 1974; 34: 738-46
7. Sauer H, Hantke U, Wilmanns W. Azathioprine lymphotoxicity. Potentially lethal damage by its imidazole derivatives. Arzneimittel Forschung 1988; 38: 820-4
8. Herber S, Lennard L, Lilleyman JS, et al. 6-Mercaptopurine: apparent lack of relation between prescribed dose and biological effect in children with leukaemia. Br J Cancer 1982; 46: 138-41
9. Lennard L, Rees CA, Lilleyman JS, et al. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 1983; 16: 359-63
10. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine in dermatologic patients. Arch Dermatol 1995; 131: 193-7
11. Huilgol SC, Black MM. Management of the immunobullous disorders. I. Pemphigoid. Clin Exp Dermatol 1995; 20: 189-201
12. Anstey A. Management of the immunobullous disorders. The clinical significance of interindividual variation in azathioprine metabolism. Clin Exp Dermatol 1996; 21: 244-51
13. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenetic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Gent 1980; 32: 651-2
14. Grant DM, Tang BK, Campbell ME, et al. Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol 1986; 21: 454-8
15. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-54
16. Bunch TW, Worthington JW, Combs JJ, et al. Azathioprine with prednisolone for polymyositis. A controlled clinical trial. Ann Intern Med 1980; 92: 365-9
17. Bunch TW. Prednisolone and azathioprine for polymyositis. Long-term follow up. Arthritis Rheum 1981; 24: 45-8
18. Sztejnbok M, Stewart A, Diamond H, et al. Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum 1971; 14: 639-45
19. Mason M, Currey HLF, Barnes CG, et al. Azathioprine in rheumatoid arthritis. BMJ 1969; 1: 420-2
20. Witte AS, Cornblath DR, Schatz NJ, et al. Monitoring azathioprine therapy in myasthenia gravis. Neurology 1986; 36: 1533-4
21. Wickramasinghe SN, Dodsworth H, Rault RMJ, et al. Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation. Transplantation 1974; 18: 443-6
22. McGrath BP, Ibels LS, Raik E, et al. Erythroid toxicity of azathioprine. Macrocytosis and selective marrow hypoplasia. Q J Med 1975; 96: 57-63
23. Johnston FA, McGill PE. Azathioprine in advanced rheumatoid arthritis in old age. J Clin Exp Gerontol 1989; 11: 87-95
24. Bystryn J-C, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996; 132: 203-12
25. Anstey A. Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics. J R Soc Med 1995; 88: 155p-60p
26. Guillaume J-C, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49-53
27. Anstey A. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 1203-4
28. Board JA, Lee HM, Draper DA, et al. Pregnancy following kidney homo-transplantation from a non-twin. Report of a case with concurrent administration of azathioprine and prednisolone. Obstet Gynecol 1967; 29: 318-23
29. Kaufman JJ, Dignam W, Goodwin WE, et al. Successful normal childbirth after kidney homo-transplantation. JAMA 1967; 200: 338-41
30. Wing AJ. Successful pregnancies in women treated by dialysis and kidney transplantation. Report from the Registration Committee of the European Dialysis and Transplantation Association. Br J Obstet Gynaecol 1980; 87: 839-45
31. Gebhardt DO. Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol 1983; 61: 270
32. Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol 1973; 115: 1100-6
33. Davison JM, Dellagrammatikas H, Parkin JM. Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol 1985; 92: 233-9
34. MacDougall LG, McElligott SE, Ross E, et al. Pattern of 6-mercaptopurine urinary excretion in children with acute lymphoblastic leukaemia: urinary assays as a measure of drug compliance. Ther Drug Monit 1992; 14: 371-5
35. Davies HA, Lennard L, Lilleyman JS. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance? BMJ 1993; 306: 1239-40
36. Mertens HG, Hertel G, Reuther P, et al. Effect of immunosuppressive drugs (azathioprine). Ann NY Acad Sci 1981; 377: 691-9
37. Lorenzen I, Brun C, Videbaek A. Treatment of immunological diseases with cytostatics. Acta Med Scand 1969; 185: 501-6
38. Ginzler E, Sharon E, Diamond H, et al. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 1975; 18: 27-34
39. Lennard L, Murphy MF, Maddocks JL. Severe megaloblastic anaemia associated with abnormal azathioprine metabolism. Br J Clin Pharmacol 1984; 17: 171-2
40. Old CW, Flannery EP, Grogan TM, et al. Azathioprine-induced pure red blood cell aplasia. JAMA 1978; 240: 552-4
41. Jeurissen ME, Boerbooms AM, Van De Putte LB. Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis 1988; 47: 503-5
42. Anstey A, Lennard L, Mayou SC, et al. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med 1992; 85: 752-6
43. Rawlins MD. Spontaneous reporting of adverse drug reactions. I. The data. Br J Clin Pharmacol 1988; 26: 1-5
44. Githens JH, Rosenkrantz JG, Tunnock SM. Teratogenic effects of azathioprine (Immuran). J Pediatr 1965; 66: 959-61
45. Walder BK, Robertson MR, Jeremy D. Skin cancer and immunosuppression. Lancet 1971; II: 1282-3
46. McLelland J, Rees A, Williams G, et al. The incidence of immunosuppression-related skin disease in long-term transplant patients. Transplantation 1988; 46: 871-4
47. Lewis P, Hazleman BL, Hanka R, et al. Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. Ann Rheum Dis 1980; 39: 457-61
48. Hazleman BL, De Silva M. The comparative incidence of malignant disease in rheumatoid arthritis exposed to different treatment regimens. Ann Rheum Dis 1982; 41 Suppl. I: 12-7
49. Silman AJ, Petrie J, Hazleman B, et al. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow-up study. Ann Rheum Dis 1988; 47: 988-2
50. Kinlen J, Sheil AG, Peto J, et al. Collaborative United Kingdom - Australasian study of cancer in patients treated with immunosuppressive drugs. BMJ 1979; 2: 1461-6
51. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-52
52. Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996; 46: 1607-2
53. Whisnant JK, Pelky J. Rheumatoid arthritis: treatment with azathioprine. Clinical side effects and laboratory abnormalities. Ann Rheum Dis 1982; 41 Suppl. I: 44-7
54. Jeurissen MEC, Boerbooms AMTh, van de Putte LBA, et al. Azathioprine induced fever, chills, rash, and hepatotoxicity in rheumatoid arthritis. Ann Rheum Dis 1990; 49: 25-7
55. Knowles SR, Gupta AK, Shear NH, et al. Azathioprine hypersensitivity-like reactions - a case report and review of the literature. Clin Exp Dermatol 1995; 20: 353-6
56. Saway PA, Heck LW, Bonner JR, et al. Azathioprine hypersensitivity. Case report and review of the literature. Am J Med 1988; 84: 960-4
57. Cunningham T, Barraclough D, Muirden K. Azathioprine-induced shock. BMJ 1981; 283: 823-4
58. Keystone EC, Schabas R. Hypotension with oliguria: a side effect of azathioprine. Arthritis Rheum 1981; 24: 1453-4
59. Rosenthal E. Azathioprine shock. Postgrad Med J 1986; 62: 677-8
60. Kawanishi H, Rudolph E, Bull FE. Azathioprine-induced acute pancreatitis. N Engl J Med 1973; 289: 357
61. Nogueira JR, Freedman MA. Acute pancreatitis as a complication of Immuran therapy in regional enteritis. Gastroenterology 1972; 62: 1040
62. Singleton JW, Lan DH, Kelley ML, et al. National cooperative Crohn's disease study: adverse reactions to study drugs. Gastroenterology 1979; 77: 870-2
63. Degott C, Rueff B, Kreis H, et al. Peliosis hepatis in recipients of renal transplants. Gut 1978; 19: 748-53
64. Ware AJ, Luhy JP, Hollinger B, et al. Etiology of liver disease in renal-transplant patients. Ann Intern Med 1979; 91: 364-71
65. Menard DB, Gisselbrecht C, Marty M, et al. Antineoplastic agents and the liver. Gastroenterology 1980; 78: 142-64
66. du Vivier A, Munro DD, Verbov J. Treatment of psoriasis with azathioprine. BMJ 1974; I: 49-51
67. Carmichael DJ, Hamilton DV, Evans DB, et al. Interstitial pneumonitis secondary to azathioprine in a renal transplant patient. Thorax 1983; 38: 951-2
68. Krowka MJ, Breuer RI, Kehoe TJ. Azathioprine associated pulmonary dysfunction. Chest 1983; 83: 696-8
69. Ramsey PG, Rubin RH, Tolkoff-Rubin NE, et al. The renal transplant patient with fever and pulmonary infiltrates: etiology, clinical manifestations, and management. Medicine 1980; 59: 206-2
70. L'Epplattenier JL, Binswanger U, Ott F, et al. Dermatologische komplikationen bei immunsupprimierten patienten nach nierentransplantation. Schweiz Med Wochenschr 1980; 110: 1307-
71. Bacon BR,Treuhaft WH, Goodman AM. Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases. Arch Intern Med 1981; 141: 223-6
72. Rundles WR, Wyngaarden JB, Hitchings GH, et al. Effects of a xanthine oxidase inhibitor on thiopurine metabolism. hyperuricaemia and gout. Trans Assoc Am Physicians 1963; 76: 126-40
73. Rivier G, Khamashta MA, Hughes GRV. Warfarin and azathioprine: a drug interaction does exist. Am J Med 1993; 95: 342
74. Weinshilboum RM, Sladek S, Klumpp S. Human erythrocyte thiol methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1979; 97: 59-71
75. Jacqz-Aigrain E, Bessa E, Medard Y, et al. Thiopurine methyltransferase activity in a French population: HPLC assay conditions and effect of drugs and inhibitors. Br J Clin Pharmacol 1994; 38: 1-8
76. Lennard L, Singleton HJ. High performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatogr B Biomed Appl 1994; 661: 25-33
77. Younger IR, Harris DW, Colver GB. Azathioprine in dermatology. J Am Acad Dermatol 1991; 25: 281-6
78. Lynde CW, Ongley RC, Rigg JM. Juvenile pemphigus vulgaris. Arch Dermatol 1984; 120: 1098-9
79. Tan BB, Lear JT, Gawkrodger DJ, et al. Azathioprine in dermatology: a survey of current practice in the United Kingdom. Br J Dermatol 1997; 136: 351-5
80. Ramirez G, Asherson RA, Khamashta MA, et al. Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment Semin Arthritis Rheum 1990; 20: 114-20
81. Venables PJ. Diagnosis and treatment of systemic lupus erythematosus. BMJ 1993; 307: 663
82. Redford TW, Small RE. Update on pharmacology of systemic lupus erythematosus. Am J Health-System Pharm 1995; 52: 2686-95
83. Ward JR, Williams HJ. Interim observations on benefit/risk of azathioprine versus D-penicillamine in the treatment of rheumatoid arthritis. Ann Rheum Dis 1982; 41 Suppl. I: 23-9
84. van Wanghe P, Dequerker J. Compliance and long-term effect of azathioprine in 65 rheumatoid arthritis cases. Ann Rheum Dis 1982; 41 Suppl. 1: 40-3
85. Levy J, Paulus HE, Bangert R. Comparison of azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Arthritis Rheum 1975; 18: 412-3
86. Dale I. The treatment of rheumatoid arthritis with azathioprine. Scand J Rheumatol 1972; 1: 125-7
87. Kvien TK, Hoycraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis. A single centre double blind comparative study. J Rheumatol 1986; 13: 118-23
88. Jansen GT, Barraza DF, Ballard JL, et al. Generalised seleroderma: treatment with an immunosuppressive agent. Arch Dermatol 1968; 97: 690-8
89. Kurwa AR, Denman AM. Scleroderma treated with immunosuppressive drugs. Br J Dermatol 1979; 101: 56-7
90. Van den Hoogen FHJ, Boerbooms AMT, van de Putte LBA. Effects of immunomodulating therapy in systemic sclerosis. Clin Rheumatol 1990; 9: 319-24
91. Vallance DK, Lynch III JR, McCune JW. Immunosuppressive treatment of the pulmonary manifestastations of progressive systemic sclerosis. Curr Opin Rheumatol 1995; 7: 174-82
92. Kolle G. Bone marrow damage following immunosuppressive therapy with azathioprine of juvenile rheumatoid arthritis and the Still syndrome [in German]. Dtsch Med Wochenschr 1969; 94: 2268-2273
93. Verhelst JA, Van Den Enden E, Mathys R. Rapidly evolving azathioprine-induced pancytopenia. J Rheumatol 1987; 14: 862
94. Nossent JC, Swaak AJG. Pancytopenia in systemic lupus erythematosus related to azathioprine. J Intern Med 1990; 227: 69-72
95. Speerstra F, Boerbooms AMT, van de Putte LB, et al. Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years experience. Ann Rheum Dis 1982; 41 Suppl.: 37-9
96. Kerstens PJ, Stolk JN, De Abreu RA, et al. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 142-5
97. Kerstens PJ, Stolk JN, Boerbooms AM, et al. Purine enzymes in rheumatoid arthritis. A clue to the prediction of the response to azathioprine? Review and hypothesis. Clin Exp Rheumatol 1995; 13: 107-1
98. Schmiegelow K, Kriegbaum NJ. 6-Thioguanine nucleotide accumulation in erythrocytes during azathioprine treatment for systemic connective tissue diseases: a possible index for monitoring treatment. Ann Rheum Dis 1993; 52: 152-4
99. Ebers GC. Treatment of multiple sclerosis. Lancet 1994; 343: 275-9
100. Tucker WG, Kapphahn KH. A preliminary evaluation of azathioprine in the treatment of multiple sclerosis. Henry Ford Hosp Med J 1969; 17: 89-91
101. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment of multiple sclerosis. Lancet 1991; 338: 1051-5
102. Ellison GW, Myers LW, Mickey MR, et al. A placebo-controlled, randomised, double masked variable dosage, clinical trial of azathioprine with and without methyl prednisolone in multiple sclerosis. Neurology 1989; 39: 1018-26
103. Kinkel RP, Goodkin DE. Immunotherapy for multiple sclerosis. A review of the clinical experience. Clin Immunother 1994; 1: 117-34
104. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 1997; 350: 261
105. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797-810
106. Mertens HG, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressant agents. Eur Neurol 1969; 2: 321-9
107. Fonseca V, Harvard CW. Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J 1990; 66: 102-5
108. Matell G. Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. Ann NY Acad Sci 1987; 505: 589-94
109. Hohlfield R, Toyka K, Besinger U, et al. Reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985; 17: 238-42
110. Shah A, Lisak RP. Immunopharmacologic therapy in myasthenia gravis. Clin Neuropharmacol 1993; 16: 97-103
111. Kamm MA, Senapati A. Drug management of ulcerative colitis, BMJ 1992; 305: 35-8
112. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-
113. Bell C. Therapeutic options in inflammatory bowel disease. Clin Ther 1995; 36: 35-42
114. Choi PM, Targan SR. Immunomodulator therapy in inflammatory bowel disease. Dig Dis Sci 1994; 39: 1885-92
115. Lobo AJ, Foster PN, Burke DA, et al. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990; 33: 374-7
116. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. BMJ 1982; 284: 1291-2
117. Brookc BN, Hoffmann DC, Swarbrick ET. Azathioprine for Crohn's disease. Lancet 1969; II: 612-4
118. Rhodes J, Bainton D, Beck P, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; II: 1273-6
119. Willoughby JM, Beckett J, Kumar PJ, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; II: 944-7
120. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7
121. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta analysis. Ann Intern Med 1995; 123: 132-42
122. Sandborn WJ, Van Os EC, Zins BJ, et al. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995; 109: 1808-7
123. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in chronic active hepatitis. Q J Med 1971; 40: 159-85
124. Hegarty JE, Nouri Aria KT, Portmann B, et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983; 3: 685-9
125. Vegnente A, Larcher VF, Mowat AP, et al. Duration of chronic active hepatitis and the development of cirrhosis. Arch Dis Child 1984; 59: 330-5
126. Maggiore G, Bernard O, Hadchouel M, et al. Treatment of autoimmune chronic active hepatitis in childhood. J Pediatr 1984; 104: 839-44
127. Stellon AJ, Hegarty JE, Portmann B, et al. Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1985; I: 668-70
128. Stellon AJ, Keating JJ, Johnson PJ, et al. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988; 8: 781-4
129. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-63
130. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-7
131. Jardim HM, Leake J, Risdon RA, et al. Crescentic glomerulonephritis in children. Pediatr Nephrol 1992; 6: 231-5
132. Brahm M, Brammer M, Balslov JT, et al. Prognosis in glomerulonephritis. III. A longitudinal analysis of changes in serum creatinine and proteinuria during the course of disease: effect of immunosuppressive treatment. Report from Copenhagen Study Group of Renal Diseases. J Intern Med 1992; 231: 339-47
133. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisolone over prednisolone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984; 311: 1528-33
134. de Glas-Vos JW, Krediet RT, Weening JJ, et al. Treatment of proliferative lupus nephritis with methylprednisolone pulse therapy and oral azathioprine. Neth J Med 1995; 46: 4-14
135. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisolone only. Arthritis Rheum 1991; 34: 945-50
136. Chan T-M, Li F-K, Wong RWS, et al. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995; 71: 321-7
137. Banfi G, Moriggi M, Sahadini E, et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991; 36: 53-9
138. Cameron JS. Treatment of primary glomerulonephritis using immunosuppressive agents. Am J Nephrol 1989; 9 Suppl. 1: 33-40
139. Cameron JS, Turner DR, Ogg CS, et al. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978; 10: 213-8
140. Shapiro DL, Spiera H. Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Arthritis Rheum 1995; 38: 1851-4